Saturday, June 13, Beam’s VP & Head of Clinical Bioanalytics & Translational Sciences Priya S. Chockalingam will present at EHA 2026, sharing updated biomarker data on RBC health & function from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in SCD.

I've finished accumulating my position in IIQ and wanted to share why I’m genuinely excited about the story. After reviewing the latest quarterly, company presentations, and recent YouTube videos (especially Leearne Hinch’s updates), the progress is clear. They’re methodically de-risking both the EXO-OC ovarian cancer screening test and their CAR-exosome therapeutic platform. The March quarterly showed a solid cash balance (~$11.9m), controlled burn, and steady advancement across the pipeline. The standout item for me is the recent study referenced by Mercy BioAnalytics’ CSO (Toumy G.). It’s the same research led by Professor Carlos Salomon (UQ professor and scientific advisor to Inoviq). The study showed that EV-based classifiers significantly improved sensitivity and specificity when combined with CA-125, with strong performance maintained across plasma and serum samples. This directly supports Inoviq’s exosome approach and reinforces the potential of their EXO-OC test as a genuine game-changer for early ovarian cancer detection. Near-term catalyst: The expanded ~2,000 sample EXO-OC study results are due in June 2026 — this is the big one that could validate the test’s real-world performance. Investment Thesis IIQ sits at the sweet spot of a high-conviction exosome platform: a potentially best-in-class early detection test for one of the deadliest cancers a novel CAR-exosome therapeutic program that could offer major advantages over traditional cell therapies. They have strong scientific backing, growing EXO-NET commercial traction, and a clear path toward LDT commercialisation in the US. Of course, it’s still biotech — execution risk, further funding needs, and clinical/regulatory hurdles remain. However, with the science continuing to stack up and key data readouts imminent, I believe the risk/reward is very attractive at current levels. Happy to be a long-term holder here. #IIQ #ExosomeTech #OvarianCancer

🔴 Estamos en vivo desde la FILBo Acompáñanos en la presentación del libro “Gabinete de curiosidades de insectos” con su autor Jorge Alberto Molina, profesor y vicedecano académico de nuestra Facultad de Ciencias, junto a Sofía Medellín Becerra, bióloga especializada en ecología y bioacústica, Co-fundadora de Bioanalytics. 👉 Conéctate ahora youtube.com/live/P5myjsZuyaM…

Very excited to debut our latest work in ophthalmic bioanalytics at @ARVOinfo 2026 annual meeting. Come visit the @EyeCRO booth and say hello! I would love to learn more about your needs or interests in proteomics, metabolomics, lipidomics, genomics, and/or small molecule discovery! eyecro.com/one-cro-complete-…

HBTU opens admission for M.Sc Biotechnology M.Sc Biochemistry M.Sc Forensic Bio analytics Apply Here : hbtuadm.samarth.edu.in/ #biotechnology #bioinformatics #bioanalytics #hbtu #hbtukanpur #kanpur

In 2025, the EMA and FDA each released regulatory guidance that impacts the development and approval processes for #biosimilars. Find out what this means for analytics and bioanalytics, clinical study design and commercialisation in our whitepaper. ow.ly/uhph50YsIYe

Gustitus, TS/SCI cleared Operations Research Analyst within the 711th Human Performance Wing, the same organization that runs applied cognitive neuroscience, tDCS brain stimulation research, and directed energy bioeffects programs, the operational inheritor of every classified EM-to-biology program the CIA was translating from Soviet research in the 1970s. Casias, LANL administrative assistant, inside the same institution that runs genomics and bioanalytics for national security biosurveillance, multi-omics research, DNA data storage, and pathogen signature discovery, rooted in their foundational role in the Human Genome Project. Reza, a materials scientist whose superalloy work fed directly into AFRL propulsion programs, specifically through McCasland’s command of the Space Vehicles Directorate and Phillips Research Site at Kirtland, the same base that also houses AFRL’s Directed Energy Directorate, the physical infrastructure layer underneath every directed energy and bioeffects delivery system that needs a platform. McCasland, the former AFRL commander who controlled the budget ecosystem, funding all of it, directed energy, advanced materials, and human performance. Loureiro, plasma physicist and Los Alamos Ulam Distinguished Scholar, whose magnetic reconnection and plasma turbulence work underpins the physics of directed energy systems, and who was actively developing quantum computing algorithms for plasma simulation, which is exactly the AI-physics convergence layer these programs need to move from experimental to operational. Grillmair, running sensor validation and instrument characterization for the same infrared detection pipeline that, in a military context, maps directly onto the targeting and tracking backbone for directed energy delivery and adversarial space object surveillance Put it all together, and you get a map and the ability to build the programs I've been posting about for the past 3 years. It boils down to Neuroweapons/DEW, AI, and genetics/cognitive enhancement/manipulation.

We are adding world-class expertise to our Scientific Advisory Board at @proximabio Dr. Raymond Deshaies: co-inventor of PROTACs, National Academy of Sciences member, fmr SVP Global Research at Amgen Dr. Lyn Jones (@LynJonesChemBio): molecular glue leader, fmr Head of Chemical Biology at Pfizer, PI at Dana-Farber Dr. Juri Rappsilber (@RappsilberJuri): pioneer of cross-linking mass spectrometry, Chair of Bioanalytics at TU Berlin We're excited to tap their deep expertise in target biology, medicinal chemistry, and structural proteomics as we build the platform for rational design of proximity-based medicines. Press release: bit.ly/4d4dYwV

Haha actually my day job. I’m the director of pharmacology and bioanalytics M-F 9-5 and slang sauce in the evenings and weekends. I do lots of cool people science in the evenings and weekends though! Nice to meet you JD. Those @UNDEFEATED_BRO @Undefeated_bae folks are awesome!!

That would be a "Bioanalytics technician" (Bioanalytiker) the non danish version of medico technician. Yeah the robot lines are somewhat sensitive

Yup. Making electroporators, bioreactors, tissue culture incubators, hoods, protein purification equipment, bioanalytics… so many little things that are otherwise stuck in 80-90s tech with reskinned software, and repackaged for max profit. The day of reckoning has come and now biotech is dominated by CROs..

🧬 Just out in Bioinformatics Advances: “Omics BioAnalytics: An RShiny application for multimodal biomarker panel discovery and assessment”  Full article available at doi.org/10.1093/bioadv/vbaf3…  Authors include: @hearthock, @asingh_22g

Syngene’s Big Leap: First Global Phase III Trial Deal & T&CR Growth Insights 🔬📈 | MCap 26,110.47 Cr - Syngene announced a deal for its first global Phase III clinical trial with a U.S.-based biotech company (Q2 FY26). - The global clinical trials market is valued at ~$60B, growing at 11% CAGR. - APAC (including India) is a high-growth region, with India’s CRO market projected at 16% CAGR (2024-28). - Syngene’s T&CR services include Human Pharmacology, Clinical Trial Services, Bioanalytics, and Central Lab Services. - Completed 800 BA/BE studies for regulated markets and partnered with 180 global clinical sites. - Strategic focus: Supporting complex/new modalities and forward integration into later trial phases. - Differentiators: Integrated platform, regulatory excellence, and global compliance standards. - Investor webinar on Dec 17, 2025, to discuss T&CR business (no financial disclosures). Complete Source: bseindia.com/xml-data/corpfi… Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision. Preview 👇 (First 4 out of 21 pages)

📢Job Alert: PhD Position at the Chair of Chemistry of Biogenic Resources, @TU_Muenchen 💶TV-L E13 (65%) 🔗cs.tum.de/en/tumcs/campus/ca… (under Chemistry of Biogenic Resources) #ResearchInBavaria #ResearchJobsInBavaria #PhDPositions #Biocatalysis #ProteinChemistry #Bioanalytics

.@AMSbiopharma Application of Biomarkers in Bioanalytics: Enabling Translational Development in Pharmaceutical R&D biotech-spain.com/en/article…

How can we treat cancer at the level of the #proteome? Find out from Bernhard Küster (Chair of Proteomics and Bioanalytics, Technical University of Munich) at The Festival of Genomics and Biodata! More info: hubs.la/Q03NHRm20 #FOG2026

The AI-powered bioanalytics company NucleicAI.com, founded by Harvard geneticists Alireza Haghighi & David Sinclair, takes another big step forward, building a global AI infrastructure to advance longevity science & affordable healthcare for all tinyurl.com/fdn8ckd9

前職投資先のMercy BioAnalyticsのシリーズB、卵巣がんの診断検査なのでFemtech Insiderにも記事載りました。おめでたい。女性の健康に貢献するライフサイエンス技術は引き続き注目しています。 femtechinsider.com/mercy-bio…

Mercy BioAnalytics Raises $59 Million Series B for Early Ovarian Cancer Detection Technology femtechinsider.com/mercy-bio…

Join us for the 11th session of our Only One Analytical Technique Talk Series! Size Exclusion Chromatography with MALS as a Critical Tool in Protein Aggregate Characterization 📅 30 Sep | 4-5 PM IST Register for free here: tinyurl.com/mry7aeua #webinaralert #bioanalytics